BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to ...

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...

Palo Alto Networks (NASDAQ: PANW) investors just cannot catch a break. Over the past three days, this cybersecurity stock has ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...